Home/CiVi Biopharma/Wade Benton

WB

Wade Benton

Chief Development Officer, Orphan Drugs

Therapeutic Areas

Cardiovascular Metabolic Orphan Diseases

CiVi Biopharma Pipeline

Drug	Indication	Phase
CiVi 030	Severe Frostbite	Phase 3
CiVi 008	Hypercholesterolemia and Prevention of Atherosclerotic Cardiovascular Disease (ASCVD)	Pre-clinical

Leadership Team at CiVi Biopharma

Shal Jacobovitz

Chief Executive Officer

Founder, Chief Scientific Officer

Chief Development Officer

Christopher Fuglesang

Chairman of the Board

View full CiVi Biopharma profile